Indication intelligence, analysis and sector perception

Sangamo Bioscience (SGMO) new data demonstrates sustained functional control of viral load - HOLD

September 21, 2015 11:09am

The prolonged positive effects observed in these Cohort 3 subjects have not been seen before with other treatments and has encouraged SGMO to enroll and treat an additional five subjects with this regimen. SGMO closed at $7.35 and is UP +$0.17 or +2.31% to $7.52 on 230.4 K share volume <3 month average = 1.2 M shares>. Can it return to the August ’15 $8.00 range? - HOLD

SGMO presented data demonstrating sustained functional control of viral load in the absence of antiretroviral drugs (:ART) in two of three HIV-infected subjects treated in Cohort 3 of its P1/2 study (SB-728-1101) of its ZFP Therapeutic (SB-728-T) for the treatment of HIV/AIDS. The subjects remain on extended treatment interruption, past the initial 16 week TI period.

In the absence of ART drugs in two HIV-infected subjects treated in Cohort 3 of its P1/2 study of SB-728-T

SGMO presented the updated clinical data at this year's ICAAC meeting from the SB-728-T trial.

The Bottom Line: The ability of subjects to suppress and sustain control of viral load, combined with durable increases in CD4 and CD8 cells provides support for the hypothesis of an immunologic mechanism of action for SB-728.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

30 min ago
RegMed Investors (RMi) Closing Bell: hammered

9 hours 21 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.